Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 25th Preview)
-
Regulators – MS therapy approvals split across US and EU
Sanofi’s tolebrutinib (Cenrifki) avoided a repeat of its US rejection as the EMA’s CHMP recommended approval for patients with non-relapsing secondary progressive multiple sclerosis. The CHMP opinion diverges from the FDA’s December complete response letter, which previously blocked US approval on safety grounds. The European recommendation is grounded in the 1,131-patient Phase III HERCULES trial, supported by GEMINI 1 and GEMINI 2 data in relapsing MS. CHMP concluded the drug delivered risk reductions in disability progression and lesion dynamics versus placebo, positioning Cenrifki for an EU first approval in the defined patient group. Separately, the CHMP also issued a positive opinion for Arrowhead’s APOC3-targeting siRNA, Redemplo, for familial chylomicronemia syndrome—an EU first if approved. The combination of an MS path cleared in Europe and lipid therapy momentum highlights how trans-Atlantic review outcomes remain highly program- and patient-subset dependent.
-
C-suite and execution – Inventiva reshuffles leadership ahead of MASH readout
Inventiva overhauled senior leadership as it heads toward a late-stage decision point for lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH). The French biotech named Axel-Sven Malkomes as CFO, Susan Coles as chief legal officer, and Pamela Herbster as chief people officer, replacing prior role holders as Jean Volatier shifts to EVP finance & corporate social responsibility. The personnel changes arrive with the company looking to a Phase III readout scheduled for 4Q26 for lanifibranor. Inventiva’s strategy now hinges on meeting clinical endpoints in MASH, where payer and guideline scrutiny can heavily influence market uptake even after positive efficacy signals. The revamped C-suite suggests the company is prioritizing operational readiness and governance as it approaches the most execution-sensitive phase of its development timeline.
-
Gene therapy – First-in-class hearing loss approval with voucher economics
Regeneron won FDA approval for Otarmeni (lunsotogene parvec), an AAV-mediated gene therapy for a rare inherited form of hearing loss caused by otoferlin variants. The decision makes the therapy the first gene treatment cleared under the FDA’s “national priority voucher” program, with Regeneron planning to offer Otarmeni at no cost to eligible US patients. The approval matters both clinically and commercially: the national priority voucher attached to the regulatory milestone can be monetized, providing a potential funding lever tied to development of future assets. Regeneron emphasized the clinical intent with an access-focused offering plan. The FDA’s action also reinforces how the voucher program is shaping gene-therapy development incentives, linking review pathways to downstream financial flexibility while still requiring evidence for safety and efficacy.
-
Clinical/regulatory – Aneurysmal SAH program hits CRL despite prior trial support
Grace Therapeutics received a US FDA complete response letter for its GTx-104 NDA for aneurysmal subarachnoid hemorrhage, delaying the company’s push to update the standard of care. The FDA cited manufacturing and nonclinical deficiencies rather than concerns about efficacy or safety. In particular, the CRL flagged leachables for product packaging, gaps in nonclinical product toxicology risk assessments, and manufacturing deficiencies at the company’s contract manufacturing organization. Grace said it plans to request a type A meeting with the FDA to clarify a path forward. For investors and clinicians, the key takeaway is that a drug’s clinical momentum can be stalled by CMC and toxicology completeness—underscoring the scrutiny placed on late-stage readiness for difficult, time-sensitive neurologic indications.
-
Cell therapy licensing – UCB buys Neurona as neurology dealmaking stays hot
UCB agreed to acquire Neurona Therapeutics for up to $1.15 billion, with $650 million paid upfront and the remainder tied to milestones. The deal targets epilepsy through Neurona’s lead asset NRTX-1001. The acquisition arrives amid an active wave of neurology transactions in 2026, as big pharma expands its toolkits across seizure disorders and other CNS diseases where late-stage or platform bets can be difficult to source internally. For Neurona and UCB, the immediate focus becomes regulatory and clinical execution around NRTX-1001 while integrating the development roadmap into UCB’s broader neuroscience pipeline.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.